Grants and Contributions:
Title:
Polyclonal Antibody Sequencing from the Blood of Recovered COVID-19 Patient Donors for Antibody Therapeutic Discovery
Agreement Number:
953239
Agreement Value:
$150,000.00
Agreement Date:
Jun 1, 2020 - Mar 31, 2021
Description:
We will use our antibody protein sequencing technology to deliver antibody sequences from human donors recovered from COVID-19 to expedite therapeutic development, and in turn begin establishing an antibody bank for coronavirus and future pandemic surveillance.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Kitchener, Ontario, CA N2G 4X8
Reference Number:
172-2020-2021-Q2-953239
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
804554392
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 5,000 dollars.
Amendment Date
Mar 8, 2021
Recipient's Legal Name:
Rapid Novor Inc.
Federal Riding Name:
Kitchener Centre
Federal Riding Number:
35045
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
54171
Amendments: